AAV-hSyn-DIO-EGFP

SKU:BHV12400399 Fluorescent Reporter AAV
Overview
Click light‑blue chips for details
rAAV for Cre-dependent expression (DIO/FLEX design; expression in Cre+ cells) of EGFP under the hSyn promoter with EGFP as a reporter/tag (Cre-dependent).
Promoter hSyn
Transgene EGFP
Reporter/Tag EGFP
Sensor/Actuator Fluorescent reporter
Function Cre-dependent
Cell Type pan-neuronal
Available Options

Select the AAV variant that best fits your experiment. Availability and lead time may vary by option.

  • Options: Serotype (28) — AAV2/1, AAV2/2, AAV1/2, AAV2/5, AAV2/6, AAV2/6m, AAV2/6.2, AAV2/8, AAV2/9, rAAV2-retro, AAV2-PHP.eB, AAV2-B10, AAV2-PHP.S, AAV2-PAN, AAV2-DJ, AAV2-7m8, AAV2-ShH10, AAV2-Rh10, AAV2-Anc80L65, AAV2-BR1, AAV2-BI30, AAV2-SCH9, MaCPNS1, MaCPNS2, mac, AAV2/11, MyoAAV 2A, VCAP-102; Titer (2) — >=2.00E+12 vg/mL, >=1.00E+13 vg/mL; Volume: 100 uL

    Why do prices vary by serotype?
    Not all AAV capsids are created equal in a manufacturing setting.

    • Standard Tiers: Consist of well-established serotypes (like AAV8 and AAV9) that naturally produce high viral yields.
    • Specialized & Premium Tiers: Include "designer" capsids (like rAAV-retro or PHP.eB) engineered for specific tissue targeting. These variants are often more difficult for cells to package and harvest, requiring 5–10x more raw materials and labor to reach the same final concentration.

    Our pricing ensures that regardless of the complexity of the capsid you choose, you receive a product that meets our strict purity and concentration standards.

  • Lead time: options listed as “Pack-Ready” (plasmid in stock; virus made to order) typically ship in 2–4 weeks; other statuses may take longer.
  • Storage: 4°C for short term storage and 80°C for long term storage; each freeze thaw cycle reduces virus titer by 10%, repeated freeze thaws should be avoided. When storing the virus at 80°C for more than 6 months, it is recommended to redetermine the viral titer or conduct pre experimental tests of product activity before use.
  • Shipping: cold-chain shipment (typically with dry ice overnight).
  • Upon receipt: store at the recommended temperature as soon as possible; avoid repeated freeze–thaw cycles.
  • Sales terms and conditions: Please review prior to ordering.
Options selector
Catalog no. Serotype Titer Volume
AAVX-1103-21-12 AAV2/1
AAVX-1103-22-12 AAV2/2
AAVX-1103-12-12 AAV1/2
AAVX-1103-25-12 AAV2/5
AAVX-1103-26-12 AAV2/6
AAVX-1103-26m-12 AAV2/6m
AAVX-1103-26p2-12 AAV2/6.2
AAVX-1103-28-12 AAV2/8
AAVX-1103-29-12 AAV2/9
AAVX-1103-2retro-12 rAAV2-retro
AAVX-1103-2PHPpeB-12 AAV2-PHP.eB
AAVX-1103-2B10-12 AAV2-B10
AAVX-1103-2PHPpS-12 AAV2-PHP.S
AAVX-1103-2PAN-12 AAV2-PAN
AAVX-1103-2DJ-12 AAV2-DJ
AAVX-1103-27m8-12 AAV2-7m8
AAVX-1103-2ShH10-12 AAV2-ShH10
AAVX-1103-2Rh10-12 AAV2-Rh10
AAVX-1103-2Anc80L65-12 AAV2-Anc80L65
AAVX-1103-2BR1-12 AAV2-BR1
AAVX-1103-2BI30-12 AAV2-BI30
AAVX-1103-2SCH9-12 AAV2-SCH9
AAVX-1103-MaCPNS1-12 MaCPNS1
AAVX-1103-MaCPNS2-12 MaCPNS2
AAVX-1103-mac-12 mac
AAVX-1103-211-12 AAV2/11
AAVX-1103-MyoAAV2A-12 MyoAAV 2A
AAVX-1103-VCAP102-12 VCAP-102
Field Specification
Cellular Localization cytosolic
Form Liquid
Function
  • Cre-dependent
Product Type
  • Vectors & Viruses
  • Adeno-Associated Viruses (AAVs)
Promoter hSyn
Reporter EGFP
Storage 4°C for short term storage and 80°C for long term storage; each freeze thaw cycle reduces virus titer by 10%, repeated freeze thaws should be avoided. W he n storing the virus at 80°C for more than 6 months, it is recommended to redete rmine the viral titer or conduct pre experimental tests of product activity before use.

Research background

This AAV provides recombinase-based genetic access, enabling conditional control of downstream payloads in genetically defined cells. Recombinase tools are widely used to restrict expression, create intersectional logic, or enable lineage/cell-type targeting.

Mechanism and expected readouts

Recombinase expression catalyzes site-specific DNA recombination at matching target sites, permanently switching genetic states in infected cells. This can gate expression of FLEX/DIO payloads or enable intersectional strategies when combined with other recombinases.

Expression design and interpretation

Expression is driven by a promoter choice that shapes cell-type bias and expression strength; human synapsin promoter, commonly used for broad neuronal expression. The construct includes regulatory logic that controls where/when the payload is active; Cre-dependent control restricts expression to cells expressing Cre recombinase. A built-in reporter/tag supports validation and localization; GFP/EGFP provides a green fluorescent readout for expression, morphology, and targeting validation. The encoded payload is intended to support the stated experimental function (e.g., modulation, sensing, labeling, or control).

Subcellular targeting elements (when present) can bias localization and should be confirmed by imaging in your preparation.

Common research applications

  • Conditional targeting for cell-type or projection-specific experiments
  • Intersectional labeling or manipulation strategies
  • Permanent genetic switching for lineage or fate-mapping workflows

Experimental considerations

  • Verify recombination efficiency with a compatible reporter in your system
  • Account for irreversible switching when designing longitudinal studies
  • Use appropriate negative controls (no recombinase or mismatched recombinase lines)

Controls and validation

Typical validation includes confirming expression pattern and level, verifying functional activity with an assay matched to the payload (e.g., imaging, electrophysiology, pharmacology, or behavior), and using appropriate negative controls.

At present, the main purification approaches for rAAV include:

  • Ultracentrifugation density-gradient methods, using cesium chloride (CsCl) or iodixanol as the gradient medium;
  • Chemical reagent precipitation/extraction methods, mainly using PEG, ammonium sulfate, chloroform, etc.;
  • Chromatographic purification methods, primarily based on affinity and ion-exchange principles.

Depending on customers’ different application needs, we can integrate multiple methods to produce high-titer, high-purity, high-quality rAAV viral products.

Titer Determination

Quantitative PCR (qPCR) is used to measure the copy number of the rAAV genome, reported in vg/mL (vector genomes per mL).

Sample Amplification Curve

Figure 1 Sample Amplification Curve

Standard Curve

Figure 2 Standard Curve

Purity Testing

rAAV purity is assessed by protein gel electrophoresis (SDS-PAGE) to evaluate the content of rAAV capsid proteins, typically expressed as a percentage (%).

The AAV capsid is composed of three structural proteins: VP1 (~87 kDa) VP2 (~73 kDa) VP3 (~62 kDa) Therefore, three distinct bands will appear on the SDS-PAGE gel image.

SDS-PAGE Analysis showing rAAV purity ≥97%

Figure 3 SDS-PAGE analysis shows rAAV purity is ≥97%

Quality Assurance: We ensure that the data and materials provided to customers are truthful and reliable.

To choose a serotype, start with your target tissue and delivery route, then pick a capsid with a proven track record in that setting and benchmark 1–3 alternatives. For liver-directed systemic expression, AAV8 is a common first choice; for broad systemic delivery and strong cardiac performance, AAV9 is often preferred. For local CNS injections, AAV2 (or AAV1/2 for improved spread) is a reliable starting point, while rAAV2-retro is ideal when you need retrograde labeling from projection targets. For mouse brain-wide delivery by IV, AAV-PHP.eB is frequently used, and AAV-PHP.S is often selected for PNS/DRG-enriched programs. For muscle, AAV1, AAV6 (and AAV6 variants) or MyoAAV 2A are common starting points; for airway/lung, AAV5 or AAV6 are typical benchmarks. For ocular work, route matters: AAV-7m8 is often chosen for intravitreal retinal delivery, while AAV2/AAV5/Anc80L65 are common comparators depending on the target layer. If you’re unsure or working in a new model, include a broad performer like AAV-DJ and/or a small screening panel (e.g., PAN/BI30/SCH9) to quickly identify the best capsid in your exact system.

Serotype / Capsid Best-known strengths Common applications (examples)
AAV2/1 High efficiency in skeletal muscle Muscle gene expression, local delivery to muscle; neuromuscular research
AAV2/2 Reliable neuronal transduction with local CNS injection; strong history of use Local brain/spinal injections; retinal subretinal delivery; general benchmarking
AAV1/2 Hybrid capsid often used for enhanced neuronal transduction/spread CNS gene expression where improved diffusion vs AAV2 is desired
AAV2/5 Strong performance in select CNS and airway contexts CNS research; airway/respiratory delivery; retinal programs (route-dependent)
AAV2/6 Efficient in muscle and airway/lung Muscle delivery; pulmonary/airway delivery; selected ex vivo workflows
AAV2/6m AAV6 variant for enhanced entry in muscle/airway settings Higher-efficiency muscle or airway delivery (model-dependent)
AAV2/6.2 AAV6 variant used to boost muscle/airway delivery Muscle and respiratory delivery where AAV6 is a baseline
AAV2/8 High efficiency in liver Liver-directed gene expression; systemic dosing where liver is the primary target
AAV2/9 Broad systemic delivery; strong in heart and useful for CNS access in rodents Cardiac studies; systemic delivery; CNS programs (route/age dependent)
rAAV2-retro Retrograde transport in neuronal circuits Circuit mapping; projection-based targeting; retrograde labeling from injection sites
AAV2-PHP.eB Very high whole-CNS transduction in mice (systemic) Mouse brain-wide delivery for neuroscience and neurogenetics
AAV2-B10 Engineered capsid used in targeting/optimization workflows Tissue-targeting exploration and comparative capsid testing
AAV2-PHP.S Enhanced peripheral nervous system (PNS) targeting in rodents DRG/PNS studies; peripheral neurobiology (systemic delivery)
AAV2-PAN Designed for broad (“pan”) transduction in some settings Broad expression screens; programs needing wide tissue coverage
AAV2-DJ Robust, broad transduction; strong general-purpose performer High-efficiency transduction in many cell types; discovery/validation work
AAV2-7m8 Optimized for retinal delivery via intravitreal injection Retina gene delivery with intravitreal route; ocular research
AAV2-ShH10 Retinal tropism with reported preference in retinal glia Retinal biology; Müller glia–focused programs (route dependent)
AAV2-Rh10 Frequently used for CNS applications CNS delivery (local routes); neuroscience studies
AAV2-Anc80L65 Broad performance; widely used in sensory/inner ear and ocular settings Inner ear studies; ocular programs; broad benchmarking
AAV2-BR1 Enrichment for brain vasculature/endothelium BBB/endothelial targeting; neurovascular research
AAV2-BI30 Engineered capsid for targeting/optimization panels Capsid screening; tissue targeting exploration
AAV2-SCH9 Engineered capsid for targeting/optimization panels Capsid screening; comparative tissue targeting
MaCPNS1 Candidate capsid in neural delivery panels CNS/PNS capsid comparisons; screening and optimization
MaCPNS2 Candidate capsid in neural delivery panels CNS/PNS capsid comparisons; screening and optimization
mac Candidate capsid in broad screening panels Capsid screening and optimization across routes/models
AAV2/11 Used for airway/epithelial delivery in some programs Respiratory/airway targeting; comparative testing vs AAV5/6
MyoAAV 2A Optimized for skeletal muscle targeting Systemic or local muscle delivery; myopathy/neuromuscular studies
VCAP-102 Candidate capsid used for vascular/endothelial-focused programs Vascular biology; endothelial targeting studies

Can’t find the AAV you need—or require a custom design and packaging service? We offer end-to-end support for diverse research and therapeutic needs, including vector design and cloning, AAV packaging services (serotype/capsid selection and production), QC & characterization (project-appropriate testing and documentation), and library preparation for pooled or library-style workflows (project dependent). Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.

References

  • Chalfie M, Tu Y, Euskirchen G, Ward WW, Prasher DC (1994). Green fluorescent protein as a marker for gene expression. Science. DOI: 10.1126/science.8303295 [PMID: 8303295]. Original GFP/EGFP reporter paper
  • Kügler S, Kilic E, Bähr M (2003). Human synapsin 1 gene promoter confers highly neuron-specific long-term transgene expression from an adenoviral vector in the adult rat brain. Gene Ther. DOI: 10.1038/sj.gt.3301905 [PMID: 12595892]. hSyn promoter — pan-neuronal specificity
  • Ayuso E, Mingozzi F, Montane J, et al. (2010). Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Gene Ther. DOI: 10.1038/gt.2010.17 [PMID: 20237510]. Sf9/baculovirus AAV production system
  • Gradinaru V, Thompson KR, Zhang F, et al. (2007). Targeting and readout strategies for fast optical neural control in vitro and in vivo. J Neurosci. DOI: 10.1523/JNEUROSCI.3606-07.2007 [PMID: 17959775]. Double-floxed inverted open reading frame (DIO) design for Cre-dependent AAV

Get a Quote

Please use this form for bulk quantity requests or customized products.

Contact Information

Product Information

Supplier Ads Slides show

Add dynamic ads with slider